Conavi Medical launches OCTIV™ in the U.S. with first commercial placement and clinical cases

Published: 

Tom Looby, President and CEO, and Amandeep Thind, CTO, of Conavi Medical Corp., discuss the U.S. launch of OCTIV™, the Toronto-based company’s coronary imaging system that puts two complementary imaging technologies into a single catheter.

Disseminated on behalf of: Conavi Medical Corp.

OCTIV launch marks a major milestone for Conavi Medical

Tom Looby, President and CEO, and Amandeep Thind, CTO, of Conavi Medical Corp. (TSXV: CNVI | OTCQB: CNVIF), discuss the U.S. launch of OCTIV™, the Toronto-based company’s coronary imaging system that puts two complementary imaging technologies into a single catheter. With stronger guideline support for imaging-guided coronary procedures and the first U.S. clinical cases completed, Conavi is taking a significant step forward in its targeted commercial rollout.

IVUS and OCT combined in a single imaging catheter

Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are established coronary imaging tools, but products on the market typically offer one or the other. Looby explains that cost and set-up time often lead doctors to choose a single modality. IVUS provides imaging depth, while OCT offers high-resolution detail. Conavi’s OCTIV system brings both modalities into one catheter. According to Thind, “This product allows clinicians to see, side by side, both intravascular ultrasound and optical coherence tomography images of the same segment of the artery at the same time.” He adds that the images are inherently co-registered through Conavi’s proprietary technology, giving physicians complementary views in a single workflow.

Intravascular imaging market gains guideline support

“We are launching into a hot market right now,” says Looby. The market backdrop includes stronger guideline support for intravascular imaging. In the U.S., the 2025 acute coronary syndromes guideline gives IVUS or OCT a Class 1, Level A recommendation for procedural guidance in patients undergoing coronary stent implantation in the left main artery or in complex lesions. A 2024 meta-analysis published in The Lancet found a 45% relative reduction in the risk of cardiac death with intravascular imaging-guided procedures compared with angiography guidance alone. That evidence relates to IVUS- or OCT-guided procedures generally. With OCTIV now in clinical use, Conavi is entering its next commercial phase within this evolving area of interventional cardiology.

First U.S. placement brings OCTIV into clinical use

On November 2, 2026, Conavi announced its first U.S. commercial placement and completed clinical cases with OCTIV. The milestone brings the company’s next-generation, FDA-cleared hybrid imaging system into clinical use in the U.S. By combining IVUS and OCT in one catheter, OCTIV gives physicians complementary views of coronary anatomy within a single workflow. Conavi is now focused on supporting clinical use at its first site and advancing placements at additional U.S. institutions. “We believe that after they use the device, they’re going to share in our vision about how this system can drive positive outcomes for their patients,” says Thind.

Building the next phase of the U.S. rollout

Conavi completed those first cases ahead of TCT 2026 in San Diego, where the company showcased OCTIV and engaged physicians through education sessions. Its focus now is on building physician experience and advancing its targeted U.S. rollout. For investors, the next milestones will be additional cases, institutional placements, and sustained clinical use as Conavi works to establish OCTIV in the coronary imaging market.

Read Conavi Medical’s latest feature on Barchart

For a deeper look at Conavi’s U.S. launch, market opportunity, and catheter-based business model, read the company’s latest feature on Barchart, “Conavi takes on medtech giants with a two-in-one heart imaging catheter.”

Transcript

Transcript lightly edited for clarity

Tom Looby, President and CEO: We are a medical device company founded and headquartered here in Toronto, Canada. We make the world’s most complete intravascular imaging catheter.

Amandeep Thind, CTO: We started Conavi Medical because we wanted to give doctors a tool to see inside patients’ arteries, to unlock new insights and new ways of treating their patients.

Tom Looby: What’s in the market right now are excellent products that do one or the other of what we do. So, there are excellent products that do intravascular ultrasound. There are products that do optical coherence tomography. But because of the cost and the time to set these products up to be used in a case, doctors will tend to use one or the other and, again, suffer through those blind spots.

Amandeep Thind: This product allows clinicians to see, side by side, both intravascular ultrasound and optical coherence tomography images of the same segment of the artery at the same time. The images are inherently co-registered due to our proprietary technology. The FDA clearance is a huge milestone for Conavi Medical.

Tom Looby: The true goal is being used in human cases. That goal has now been reached. Conavi has completed its first U.S. commercial placement, and we’ve established our first clinical site as part of Conavi’s targeted U.S. rollout. The focus now is supporting clinical use there and putting OCTIV in the hands of clinicians at additional U.S. institutions.

We’ve been blessed with a lot of doctors who have wanted to help us out by giving us feedback. We’ve had a smaller number of those that actually helped us with the architecture of this product. They are remarking that we have the best-in-class imaging for ultrasound and perhaps best-in-class imaging for the OCT side.

Conavi’s targeted U.S. rollout is now underway at its first hospital site. The focus now is supporting clinical use there and putting OCTIV in the hands of clinicians at additional U.S. institutions.

Amandeep Thind: We believe that after they use the device, they’re going to share in our vision about how this system can drive positive outcomes for their patients.

Tom Looby: We’ve raised $10 million, and it is all dedicated to that launch for our limited market release. That’s our first opportunity to collect new data, to tell new case stories.

Conavi then took OCTIV to TCT 2026 in San Diego, one of the most important meetings in interventional cardiology, showcasing the cleared system to physicians and joining physician education sessions.

We are launching into a hot market right now. We see utilization going up, primarily because guidelines have risen to Class 1A in both the United States and Europe. So, that’s encouraging more use of imaging, because the results are extraordinary. You use imaging in a case, and you can reduce the likelihood of cardiac death post-procedure by about 45%. So, we’re now at that hotspot where the market is starting to tilt up. And again, it’s because of guidelines, gold-plated clinical evidence, and good reimbursement.

Amandeep Thind: We believe that this product is the first step in a series of innovations that Conavi will develop with our clinician partners to provide positive outcomes for our partners and their patients.

Tom Looby: At Conavi, our mission was really clear from the beginning. We wanted to provide the best, clearest imaging to doctors to achieve the best outcomes for their patients. And you now have a product like Conavi that combines the best of both modalities into the same thing for approximately the same cost. So, I think that this is the time to watch.

The short version of that is: product development is done; we don’t have to develop the marketplace, but we’re going to make some big noise here in the next year.

About Conavi Medical Corp.

Conavi Medical Corp. (TSXV: CNVI | OTCQB: CNVIF) is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries.

Learn more at conavi.com.

Follow Conavi Medical on LinkedIn and X.